BioSpace News Archive

The Collaboration Will Leverage Innovative Technology Platforms to Help Pharma Companies Develop Drugs Faster, More Efficiently and With Higher Success Rates

PolyPid Ltd. (Nasdaq: PYPD), a Phase 3 clinical-stage biopharmaceutical company focused on developing targeted, locally administered and prolonged-release therapeutics using its proprietary PLEX technology, today announced that it will report its fourth quarter and full year 2020 financial results and operational highlights

As COVID-19 activity continues in Canada, we are tracking a range of epidemiological indicators to monitor where the disease is most active, where it is spreading and how it is impacting the health of Canadians and public health, laboratory and healthcare capacity.

Valcare Medical Ltd. developer of transcatheter mitral and tricuspid valve repair and replacement solutions, announces that it has successfully completed its first-in-human transseptal delivery of the AMEND™ annuloplasty ring.

Targeting the fast growing $60 billion asset performance management (APM) market, manufacturing AI analytics leader BISTel, says its expanded global sales footprint, together with enhanced cloud, Internet of things (IoT) and AI technologies will power a wave of new intelligent AI manufacturing applications in 2021

FORUS Therapeutics launches today, bringing a new pharmaceutical company onto the Canadian landscape. With a highly-experienced and proven team, an FDA-approved product already in its pipeline, and significant financial investment secured, the Toronto -based company looks to bring innovative cancer therapies to Canadian patients

Therap’s Care Coordination (CC) documentation e-tools are a Human Services CC Commercial Off the Shelf (COTS) product on a Software as a Service (SaaS) platform.

Dr. Reddy’s Laboratories Ltd. (BSE: 500124) (NSE: DRREDDY) (NYSE: RDY) (NSEIFSC: DRREDDY along with its subsidiaries together referred to as “Dr. Reddy’s”) and Global Response Aid FZCO (GRA) today announced results from an Avigan study on moderate-severe hospitalized COVID-19 patients in Kuwait.

The Government remains committed to a national, universal pharmacare program and will accelerate steps to achieve this system including through a rare-disease strategy to help Canadian families save money on high-cost drugs.

Confluent Medical Technologies Inc. (“Confluent”) today announced an expansion of its supply agreement with Allegheny Technologies (ATI) related to the manufacture and supply of ELI Nitinol, a specialized metal alloy used primarily to produce high-performance minimally invasive medical devices and components. Under the revised agreement, Confluent will provide funding to increase the furnace capacity at ATI Spec